Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PEPD | P12955 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054783 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL1840265 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL7908918 | 0.98 | ACE (0.47) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428476 | 0.94 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428477 | 0.94 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL358379 | 0.94 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL1375025 | 0.92 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL1375029 | 0.92 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL6469164 | 0.92 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL19566169 | 0.86 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-4483905-A1 | RADIOLABELED FAP-ALPHA-AFFINITY COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2025-01-01 | — | — | EP | disclosed |
| CN-115151544-B | Beta-lactamase inhibitor and preparation thereof | 宁夏农林科学院 | 2024-08-16 | — | — | CN | disclosed |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2023162946-A1 | RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| EP-4146650-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | Ningxia Academy of Agriculture and Forestry Sciences (CN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-7132418-B2 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | disclosed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1147097-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044733-A1 | PEPTIDYL HETEROCYCLIC KETONES USEFUL AS TRYPTASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ACE 80/4885REN 610/4885LMNA 4266/4885 |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ACE 1083/4885REN 17/4885LMNA 462/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | ACE 2541/4885REN 1177/4885LMNA 4701/4885 |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | ACE 105/4885REN 990/4885LMNA 1957/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | ACE 3407/4885REN 1407/4885LMNA 1483/4885 |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | MGAM, LCT, GANAB | ACE 22/4885REN 192/4885LMNA 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.